Patients with cancers that were positive for nuclear HIF-2α expression had a significantly shorter median survival (57 months, 95% confidence interval 36–79 months) than patients with cancers that were negative for nuclear HIF-2α expression (101 months, 95% confidence interval 81–121 months). Here, EPAS1 is linked to cancer.